Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Kalaris Therapeutics (Nasdaq: KLRS) announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Rhea-AI Summary

Kalaris Therapeutics (Nasdaq: KLRS) announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The session is scheduled for Tuesday, September 15, 2026, from 4:05–4:40 p.m. EDT and will feature CEO Andrew Oxtoby and CMO Matthew Feinsod.

Kalaris is a clinical-stage biopharmaceutical company developing TH103, an investigational dual-targeting biologic currently in a Phase 1b/2 multiple ascending dose study for neovascular age-related macular degeneration (nAMD). Company management will also be available for one-on-one meetings during the conference.

News Market Reaction – KLRS

-0.12% 3.3x vol

1 alert

-0.12% Session close to close

-8.6% Trough Tracked

$91.17M Market Cap

3.3x Rel. Volume

In the Aug 31 session, KLRS declined 0.12%, reflecting a mild negative market reaction. Argus tracked a trough of -8.6% from its starting point during tracking. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Historical responses included a 1.4% move for event 1255629 and a -4.99% move for positive Phase 1a ...

Analysis

Historical responses included a 1.4% move for event 1255629 and a -4.99% move for positive Phase 1a data, showing varied reactions to company updates. The active S-3 shelf remains a financing risk to monitor.

Key Figures

Conference edition: 24th annual Trial phase: Phase 1b/2 Presentation date: September 15, 2026 +1 more

4 metrics

Conference edition 24th annual Morgan Stanley Global Healthcare Conference

Trial phase Phase 1b/2 TH103 multiple ascending dose study

Presentation date September 15, 2026 Fireside chat

Presentation time 4:05–4:40pm EDT Fireside chat

Historical Context

5 past events · Latest: Aug 11 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	2Q26 earnings report	Neutral	+1.4%	Quarterly results, pipeline progress, and cash runway update
Jul 20	Leadership appointment	Positive	-8.7%	Liisa Bayko appointed chief financial officer and principal financial officer
Jul 17	Phase 1a clinical data	Positive	-5.0%	Expanded TH103 data showed retreatment and safety findings
Jul 06	Board appointment	Positive	+3.9%	Laurie Keating appointed to board effective August 1
Jun 23	Conference presentation	Neutral	+1.6%	Phase 1a data presentation and Phase 1b/2 enrollment announcement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed three aligned and two divergent reactions, including negative reactions to both a leadership appointment and positive Phase 1a clinical data.

Key Terms

anti-vegf, HSPG, intravitreal delivery

3 terms

anti-vegf medical

"TH103, a dual-action anti-VEGF therapeutic"

Anti-VEGF describes medicines or treatments that block a protein called vascular endothelial growth factor (VEGF), which tells the body to grow new blood vessels. By shutting off that signal, these therapies can slow or stop unwanted vessel growth and leaking in diseases such as certain eye disorders and cancers. Investors watch anti-VEGF programs because they can command large markets, affect patient outcomes, and drive drug sales, royalties, and valuation like controlling a major pipeline.

HSPG medical

"concurrent heparan sulfate proteoglycan (HSPG) anchoring"

Heparan sulfate proteoglycans (HSPGs) are large molecules found on cell surfaces and in connective tissue that act like molecular Velcro, helping cells stick together, communicate, and control the movement of signaling molecules. Investors track HSPGs because they play a role in disease processes and drug targeting—changes or therapies that affect HSPGs can alter how a treatment works, influence clinical trial outcomes, and affect the commercial prospects of biotech and pharmaceutical investments.

intravitreal delivery medical

"designed for intravitreal delivery"

Injection of a drug directly into the vitreous humor, the gel-like space inside the eyeball, so the medicine reaches the retina and other internal eye tissues. It matters to investors because this route affects how often a treatment must be given, the complexity of clinical trials and regulatory review, and the costs and logistics of manufacturing and administration—similar to choosing whether to send a package to a central mailbox or hand-deliver it to the recipient’s door.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).

Details:

• Type: Fireside chat
• Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
• Date: Tuesday, September 15, 2026
• Time: 4:05 – 4:40pm EDT
• Location: New York, NY
  
  

Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

About TH103
TH103 is an investigational dual-targeting biologic with the potential to be best-in class for neovascular and exudative retinal diseases. TH103 was engineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve extended intraocular retention with enhanced VEGF inhibition through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed for intravitreal delivery, with potential applications as a treatment for exudative and/or neovascular retinal diseases, such as neovascular Age-related Macular Degeneration (nAMD), diabetic eye disease and retinal vein occlusion. TH103 is currently being investigated in a Phase 1b/2 clinical trial in patients with nAMD.

About Kalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.

For more information, visit www.kalaristx.com.

Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com

FAQ

When will Kalaris (NASDAQ: KLRS) present at the Morgan Stanley 24th Annual Global Healthcare Conference?

Kalaris will present a fireside chat on September 15, 2026, from 4:05–4:40 p.m. EDT. According to Kalaris, the session is part of the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Who will represent Kalaris (KLRS) at the Morgan Stanley 2026 Global Healthcare Conference fireside chat?

Kalaris will be represented by CEO Andrew Oxtoby and CMO Matthew Feinsod. According to Kalaris, both executives will speak during the fireside chat and be available for one-on-one investor meetings at the conference.

What is TH103, the investigational drug Kalaris (KLRS) is developing?

TH103 is an investigational dual-targeting biologic for neovascular and exudative retinal diseases. According to Kalaris, TH103 is a fully humanized recombinant fusion protein engineered for intravitreal delivery with extended intraocular retention and enhanced VEGF inhibition via VEGF receptor 1 ligand binding and HSPG anchoring.

What stage of clinical development is TH103 in for Kalaris (NASDAQ: KLRS)?

TH103 is currently in a Phase 1b/2 multiple ascending dose clinical trial for nAMD. According to Kalaris, the study is evaluating TH103 in patients with neovascular age-related macular degeneration as a potential treatment for exudative and neovascular retinal diseases.

Which retinal diseases could TH103 from Kalaris (KLRS) potentially treat?

TH103 is being developed for exudative and neovascular retinal diseases, including nAMD. According to Kalaris, potential applications also include diabetic eye disease and retinal vein occlusion, leveraging dual VEGF receptor 1 ligand binding and HSPG anchoring for enhanced intraocular retention.

How can investors request one-on-one meetings with Kalaris (KLRS) at the 2026 Morgan Stanley Global Healthcare Conference?

Investors can request one-on-one meetings by contacting their conference representative. According to Kalaris, management will be available for individual meetings during the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.